AMGEN'S CLINICAL TRIALS

Advancing oncology at the speed of life™

AMGEN®

Oncology

MULTIPLE MYELOMA



Pavurutamab (AMG 701)
HLE BiTE® platform (HLE BiTE® molecule targeting BCMA)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03287908 Amgen ID*: 20170122	First-in-Human Study of Pavurutamab in Multiple Myeloma	R	1/2



Carfilzomib†
Small molecule (proteasome inhibitor)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03091127 Amgen ID*: 20150262	Real-world Use of Carfilzomib Among Patients With Relapsed MM in Europe	C	*Observational*
NCT: 03859427 Amgen ID*: 20180015	Study of Once-Weekly vs Twice-Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)	R	3
NCT: 03158688 Amgen ID*: 20160275	Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (CANDOR)	A	3
NCT: 04191616 Amgen ID*: 20180117	Study of Carfilzomib Plus Pomalidomide and Dexamethasone in Patients With First or Second Relapse of Multiple Myeloma (SELECT)	R	2

LEUKEMIA ACUTE MYELOID LEUKEMIA

AMG 330
BiTE® platform (BiTE® molecule targeting CD33)

NCT / Amgen ID*	Study	Status	Phase
NCT: 02520427 Amgen ID*: 20120252	First-in-Human Study of AMG 330 in Adult Patients With Relapsed or Refractory AML	R	1



AMG 427
HLE BiTE® platform (HLE BiTE® molecule targeting FLT3 antigen)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03541369 Amgen ID*: 20170528	First-in-Human Study of AMG 427 in Patients With Relapsed/Refractory AML	A	1



AMG 176
Small molecule (intravenous MCL-1 inhibitor)

NCT / Amgen ID*	Study	Status	Phase
NCT: 02675452 Amgen ID*: 20150161	First-in-Human Study of AMG 176 in Relapsed or Refractory AML	R	1

LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA

Blinatumomab
BiTE® platform (BiTE® molecule targeting CD19)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03117621 Amgen ID*: 20150136	Observational Study of Blinatumomab	R	*Observational*
NCT: 04524455 Amgen ID*: 20190177	Study of Blinatumomab in Combination With AMG 404 in Adults With Relapsed or Refractory B-precursor ALL	R	1b
NCT: 04521231 Amgen ID*: 20180257	Study of Subcutaneous Blinatumomab Administration in ALL	R	1b
NCT: 04506086 Amgen ID*: 20190014	Study of Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor ALL	N	4
NCT: 04994717 Amgen ID*: 20190360	Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia	N	3



Carfilzomib†
Small molecule (proteasome inhibitor)

NCT / Amgen ID*	Study	Status	Phase
NCT: 02303821 Amgen ID*: CFZ008	Study of the Safety, Tolerability, and Activity of Carfilzomib, Alone and in Combination With Induction Chemotherapy, in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia	R	1b/2

OTHER PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

ABP 959‡
Monoclonal antibody (eculizumab biosimilar)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03818607 Amgen ID*: 20150168	Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)	A	*Clinical Comparability*

OTHER CHRONIC GRAFT VERSUS HOST DISEASE

Efavaleukin alfa (formerly AMG 592)
Fusion protein (IL-2 mutein)

NCT / Amgen ID*	Study	Status	Phase
NCT: 03422627 Amgen ID*: 20160283	Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Efavaleukin alfa in Adult Patients With Steroid-Refractory Chronic Graft Versus Host Disease	R	1b/2

P *Potentially may resume* N *Not yet recruiting* R *Active, recruiting* A *Active, not recruiting* C *Completed, pending results*

GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER

Bemarituzumab
Monoclonal antibody targeting FGFR2b

NCT / Amgen ID*		Status	Phase
NCT: 03694522	Amgen ID*: FPA144-004 Phase 2		
A Phase 2 Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)		(A)	2
NCT: 05052801	Amgen ID*: 20210096		
A Phase 3 Study of Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)		[N]	3
NCT: 05111626	Amgen ID*: 20210098		
A Phase 1b/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric/Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)		[N]	1b/3



AMG 199
HLE BiTE® platform (HLE BiTE® molecule targeting MUC17)

NCT / Amgen ID*		Status	Phase
NCT: 04117958	Amgen ID*: 20180290		
A Phase 1 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer		(R)	1

AMG 910
BiTE® platform (BiTE® molecule targeting CLDN18.2)

NCT / Amgen ID*		Status	Phase
NCT: 04260191	Amgen ID*: 20180292		
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma		(R)	1

GASTROINTESTINAL, PANCREATIC, OR COLORECTAL CANCER



Romiplostim
Protein/peptibody (thrombopoiesis stimulator)

NCT / Amgen ID*		Status	Phase
NCT: 03362177	Amgen ID*: 20140346		
Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal, Pancreatic, or Colorectal Cancer		(R)	3

LUNG CANCER NON-SMALL CELL LUNG CANCER



Acapatamab (AMG 160)
HLE BiTE® platform (HLE BiTE® molecule targeting PSMA)

NCT / Amgen ID*		Status	Phase
NCT: 04822298	Amgen ID*: 20180273		
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer		(A)	1b

LUNG CANCER NON-SMALL CELL LUNG CANCER (continued)



Sotorasib (AMG 510)
Small molecule (*KRAS*^{G12C} inhibitor)

NCT / Amgen ID*		Status	Phase
NCT: 03600883	Amgen ID*: 20170543		
CodeBreaK 100: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination Therapy With Anti-PD-1/L1 in NSCLC With *KRAS* G12C Mutation		(R)	1/2
NCT: 04185883	Amgen ID*: 20190135		
CodeBreaK 101: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With *KRAS* G12C Mutation		(R)	1b
NCT: 04380753	Amgen ID*: 20190147		
CodeBreaK 105: Open-Label Study Evaluating Sotorasib Monotherapy in Patients of Chinese Descent With Advanced Solid Tumors With *KRAS* G12C Mutation		(A)	1
NCT: 04303780	Amgen ID*: 20190009		
CodeBreaK 200: A Phase 3 Study to Compare Sotorasib With Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC With *KRAS* G12C Mutation		(A)	3
NCT: 04933695	Amgen ID*: 20190288		
CodeBreaK 201: Open Label Study of Sotorasib in Untreated Patients with Stage IV KRAS G12C-mutated NSCLC and PDL1 <1% and/or STK11 mutation		[N]	2

LUNG CANCER SMALL CELL LUNG CANCER

AMG 119
CAR T-cell therapy (anti-DLL3 CAR-T)

NCT / Amgen ID*		Status	Phase
NCT: 03392064	Amgen ID*: 20170124		
First-in-Human Study of AMG 119 to Evaluate the Safety, Tolerability, and Efficacy in Patients With RR SCLC		(P)	1



Tarlatamab (AMG 757)
HLE BiTE® platform (HLE BiTE® molecule targeting DLL3)

NCT / Amgen ID*		Status	Phase
NCT: 03319940	Amgen ID*: 20160323		
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab (AMG 757) in SCLC		(R)	1



Tarlatamab (AMG 757) + AMG 404
HLE BiTE® platform (HLE BiTE® molecule targeting DLL3) + Monoclonal antibody (Anti-PD1)

NCT / Amgen ID*		Status	Phase
NCT: 03319940	Amgen ID*: 20200439		
A Phase 1b Study Evaluating the Safety and Efficacy of Tarlatamab (AMG 757) in Combination With AMG 404 in Subjects With SCLC		(R)	1b

(P) *Potentially may resume* [N] *Not yet recruiting* (R) *Active, recruiting* (A) *Active, not recruiting* [C] *Completed, pending results*

NON-SMALL CELL LUNG, OVARIAN, OR BREAST CANCER



Romiplostim
Protein/peptibody (thrombopoiesis stimulator)

NCT: 03937154 Amgen ID*: 20170770	Status	Phase
Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Non-small Cell Lung, Ovarian, or Breast Cancer	R	3

PROSTATE CANCER



Acapatamab (AMG 160)
HLE BiTE® platform (HLE BiTE® molecule targeting PSMA)

NCT: 03792841 Amgen ID*: 20180101	Status	Phase
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab (AMG 160) in Patients With mCRPC	R	1
NCT: 04631601 Amgen ID*: 20190505	Status	Phase
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	R	1

AMG 340
UniAb® platform (bispecific T cell engager targeting PSMA and CD3)

NCT: 04740034 Amgen ID*: 20210249	Status	Phase
A Study of AMG 340 (TNB-585) in Subjects with Metastatic Castrate-resistant Prostate Carcinoma	R	1

AMG 509
XmAb® platform (XmAb® targeting STEAP1)

NCT: 04221542 Amgen ID*: 20180146	Status	Phase
Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	R	1



Tarlatamab (AMG 757)
HLE BiTE® platform (HLE BiTE® molecule targeting DLL3)

NCT: 04702737 Amgen ID*: 20200040	Status	Phase
Study Evaluating Tarlatamab (AMG 757) in Patients With De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer	N	1b

P *Potentially may resume* N *Not yet recruiting* R *Active, recruiting* A *Active, not recruiting* C *Completed, pending results*

SOLID TUMORS WITH *KRAS* G12C MUTATION



Sotorasib (AMG 510)
Small molecule (*KRAS*^{G12C} inhibitor)

NCT: 03600883 Amgen ID*: 20170543	Status	Phase
CodeBreaK 100: Open-Label Study Evaluating Sotorasib Monotherapy in Advanced Solid Tumors With *KRAS* G12C Mutation	R	1/2
NCT: 04185883 Amgen ID*: 20190135	Status	Phase
CodeBreaK 101: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With *KRAS* G12C Mutation	R	1b
NCT: 04380753 Amgen ID*: 20190147	Status	Phase
CodeBreaK 105: Open-Label Study Evaluating Sotorasib Monotherapy in Patients of Chinese Descent With Advanced Solid Tumors With *KRAS* G12C Mutation	A	1

VARIOUS SOLID TUMORS

AMG 256
Bi-functional fusion protein (Targeted IL-21 receptor agonist)

NCT: 04362748 Amgen ID*: 20180144	Status	Phase
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	R	1

AMG 404
Monoclonal antibody (Anti-PD1)

NCT: 03853109 Amgen ID*: 20180143	Status	Phase
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 404 in Patients With Advanced Solid Tumors	R	1

AMG 506** (also known as MP0310)
DARPin® protein targeting FAP x 4-1BB

NCT: 04049903 Study ID*: MP0310-CP101	Status	Phase
A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MP0310 in Patients With Advanced Solid Tumors	R	1



AMG 650
Small molecule targeting KIF18A being evaluated in advanced solid tumors

NCT: 04293094 Amgen ID*: 20190131	Status	Phase
A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors	R	1

AMG193
MTA cooperative PRMT5 inhibitor

NCT: 05094336 Amgen ID*: 20210023	Status	Phase
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	N	1/1b/2

Talimogene Laherparepvec§

Oncolytic immunotherapy (oncolytic viral therapy)

	Status	
NCT: 02756845 Amgen ID*: 20110261 Study of Talimogene Laherparepvec in Children With Advanced Non-CNS Tumors	Ⓡ	Phase 1
NCT: 03064763 Amgen ID*: 20140270 Study to Evaluate the Safety/Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma	Ⓐ	Phase 1
NCT: 02509507 Amgen ID*: 20140318 Safety Study of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318)	Ⓡ	Phase 1b/2
NCT: 03256344 Amgen ID*: 20140299 Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases	Ⓐ	Phase 1b
NCT: 04068181 Amgen ID*: 20180115 T-VEC With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)	Ⓐ	Phase 2
NCT: 02211131 Amgen ID*: 20110266 Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma	Ⓐ	Phase 2
NCT: 02910557 Amgen ID*: 20130193 Postmarketing Prospective Study of Melanoma Patients Treated With Talimogene Laherparepvec to Characterize Risk of Herpetic Infection	Ⓡ	Phase 4
NCT: 02173171 Amgen ID*: 20120139 Registry Study to Evaluate the Survival and Long-Term Safety of Patients With Melanoma Who Previously Received Talimogene Laherparepvec	Registry	*Observational*

*For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgenpipeline.com. †Sponsored by Onyx Pharmaceuticals, an Amgen subsidiary. ‡The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification. §Previously referred to as OncoVEX$^{GM\text{-}CSF}$. **AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG.

DARPin® is a registered trademark owned by Molecular Partners AG.

XmAb® is a registered trademark of Xencor.

ALL – acute lymphoblastic leukemia; AMG 193 – placeholder for now; AML – acute myelogenous leukemia; BiTE® – bispecific T-cell engager; BCMA – B-cell maturation antigen; CD – cluster of differentiation; CLDN18.2 – claudin-18 isoform 2; CNS – central nervous system; DARPin® – designed ankyrin repeat proteins; DLL3 – delta-like ligand 3; EGFR – epidermal growth factor receptor; EGFRvIII – epidermal growth factor receptor variant III; FAP – fibroblast activation protein; FGFR2b – fibroblast growth factor receptor 2b; FLT-3 – FMS-like tyrosine kinase 3; G-CSF – granulocyte colony-stimulating factor; HLE – half-life extended; ITP – immune thrombocytopenic purpura; IL-21 – interleukin-21, IV – intravenous; KRAS – Kirsten rat sarcoma 2 viral oncogene homolog; mAb – monoclonal antibody; mCRPC – metastatic castration-resistant prostate cancer; MCL-1 – myeloid cell leukemia sequence 1; MM – multiple myeloma; MUC – mucin; PD-1 – programmed cell death protein-1; PD L1 – programmed death-ligand 1; PK – pharmacokinetics; PNH – paroxysmal nocturnal hemoglobinuria; PSMA – prostate-specific membrane antigen; RR – relapsed or refractory. SCLC – small cell lung cancer; STEAP – six-transmembrane epithelial antigen of the prostate.

Information as of November 8, 2021. Statements are based on the company's current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen's filings with the SEC. Products under investigational study have not been approved by regulatory agencies for the use under investigation. This information is provided only for purposes of providing general information on clinical trials and stages of development on the select candidates identified. This information should not be construed as a recommendation for use of any product for unapproved uses.

MODALITIES

Amgen has built an array of drug modalities that is unsurpassed in the biopharmaceutical industry.

Small Molecule



BiTE® Technology



HLE BiTE® Technology



XmAb® Bispecific Antibody



Oncolytic Viral Therapy



CAR T Cell



Peptibody



Monoclonal Antibody



DARPin® Peptibody



Bi-functional Fusion Protein

Fusion Protein



UniAb® Platform



Disclaimer: Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process.
BiTE = bispecific T-cell engager; CAR = chimeric antigen receptor; HLE = half-life extended.

Amgen's Research and Development Strategy

Our Vision

Benefit patients and societies through transformative medicines.

Our Priorities

Improve our success rates: Focus our people and investments more intensely on the activities most likely to lead to new therapies.

Reduce cycle times: The industry's standard timeline of 12 to 14 years from project start to drug approval is not viable. Amgen has already reduced its drug development timelines by about three years, but there is still ample room for improvements.

Enable access and use: Gaining regulatory approval for new therapies is only half the battle. In the end, only one metric matters: Are the patients who need Amgen medicines actually getting them?

Our Strategic Imperatives

Make focused investment in innovative research platforms:

- Focus research investments in cardiometabolic, inflammation, and cancer therapeutic areas. Rapidly expand the scale and diversity of our human genetic platform.
- Expand our human data resources to include proteomics, transcriptomics, and allied data to generate deeper insights into disease biology.
- Use our strength in molecular engineering to expand on the success of current drug platforms, including BiTE® molecules, and pioneer novel modalities to address targets now seen as undruggable.

Innovate in clinical development:

- Reduce the durations and cost of clinical trials and improve success rates through greater use of modelling and simulation, adaptive designs, and real-world evidence.
- Design smaller and faster studies with larger response rates by using genetics and omics to identify patients who will potentially benefit most from new therapies.

Address access and use at all stages of drug development:

- Ensure that representatives from our medical, clinical development, commercial, and manufacturing functions are partnering with research teams very early in each drug discovery program to define the attributes a new medicine will need to gain future access and use.
- Leverage our Global Medical organization and its external network of research collaborators to generate insights into the evidence our drug development teams must generate in order to support access and use.
- Invest in biomarkers, diagnostics, and other tools that can enhance the value of our medicines and support Amgen's commitment to empower doctors to go beyond a traditional "one size fits all" approach to treat patients in a more precise, personalized way.

Our Strategic Enablers

- Maintain our long-standing and successful commitment to continuous improvement and operational efficiency in all aspects of R&D by challenging the way we work, speeding up decision making, and delivering better productivity to free resources to drive our science and innovation to deliver transformative medicines.
- The foundation for our past and future success is our people – they form the foundation for all we do. We will continue to build an R&D culture that recruits, develops, and retains the best talent excited by the opportunities arising from rapid scientific progress and new technologies to push the boundaries of science as part of a collaborative team vested in a collective accountability for our success.

AMGEN®

Oncology